Bayer Aktiengesellschaft

Farbenfabriken Bayer Aktiengesellschaft

Wulf Vater

Friedrich Bossert

Horst Meyer

Kurt Stoepel

Egbert Wehinger

Stanislav Kazda

Arend Heise

Robertson Towart

Klaus Schlossmann

Freidrich Bossert

Bodo Junge

Gerhard Franckowiak

Friedrich Hoffmeister

Anke Bentlage

Stanislay Kazda

Friedrich Bosseret

Stanislav Kaada

Reinhold Tacke

The invention relates to optically active 1,4-dihydropyridine compounds of Formulas Ia and Ib as defined hereinabove which are effective for influencing circulation. Also included in the invention are compositions containing said optically active compounds and methods for the use of said compounds and compositions.

Optically active 1,4-dihydropyridine esters useful for treating

The compound,

The invention relates to 1,4-dihydropyridines as well as methods for the preparation of said 1,4-dihydropyridines and compositions contained therein. The invention also includes the use of said compounds and compositions for influencing circulation.

Vasodilating cyanoalkyl esters of 1,4-dihydropyridines

1,4-Dihydro-2,6-dimethyl-4-(2'-chlorophenyl)-3,5-dicarboxylic

The invention provides pharmaceutical compositions and medicaments, useful for the treatment of cerebral disorders, wherein the active compound is 1,4-dihydro-2,6-dimethyl-4-(3'-nitrophenyl)-pyridine-3-(.beta.-methoxyethy l ester)-5-(isopropyl ester). Also included in the invention are methods for the use of said compositions and medicaments.

Cerebral therapeutic agent and its use

The invention provides sila-substituted 1,4-dihydropyridine derivatives useful as medicament which influence the circulation. Also included in the invention are methods for the procurement of said derivatives, compositions containing said derivatives and methods for the use of said derivatives.

Sila-substituted 1,4-dihydropyridine derivatives and their medicinal use

The present invention provides 1,4-dihydropyridine derivatives of the formula in which ##STR1## R represents hydrogen, alkyl, alkenyl, alkoxyalkyl, aryl or aralkyl, the alkyl and aryl groups being optionally substituted,

1,4-Dihydropyridine derivatives substituted in the 2 position, and their

The invention concerns the provision of novel 1,4-dihydropyridine-sugar derivatives and processes for their preparation. The invention also concerns pharmaceutical compositions containing the compounds of the invention and methods for their use. The products of the invention, such as 2-[1,4-dihydro-5-(2-propyl)-oxycarbonyl-2,6-dimethyl-4-m-nitrophenyl-3- pyridylcarbonyloxy]-ethyl .beta.-D-glucopyranoside, are effective for the treatment of circulatory disorders and can be used as antihypertensive agents, vasodilators or coronary therapeutic agents.

1,4-Dihydropyridine-sugar derivatives, and their use as medicaments

The invention includes the provision of 2-alkyleneaminodihydropyridines and salts thereof and are useful, inter alia, as coronary dilators and antihypertensive agents. Also included in the invention are pharmaceutical compositions containing said 2-alkyleneaminodihydropyridines and methods of treatment involving the use of said compounds or compositions.

2-Alkyleneaminodihydropyridines compounds, their production and their

The invention provides a novel compound, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid isopropyl 2-propoxyethyl ester and processes for its preparation. In addition, the invention includes the provision of compositions containing the compound of the invention and methods for treating warm-blooded animals for peripheral perfusion disturbances.

1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid

The invention relates to new dihydropyridines which are substituted by an amino group in at least one of the 2- and 6-positions, by a sulphur-containing substituent in the 3-position, by a cyclic substituent in the 4-position and by a carbonyl substituent in the 5-position. The new dihydropyridines are particularly useful as agents which influence the circulatory system. Also included in the invention are procedures for preparation of the new dehydropyridines, compositions containing them and methods for their use.

Sulphur-containing amino-dihydropyridines, and their use as medicants

The isobutyl methyl 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylate demonstrates the unique ability of increasing myocardial perfusion upon oral or intravenous administration. Methods of preparing the compound, its use in coronary conditions and pharmaceutical compositions for effecting that use are disclosed.

2,6-Dimethyl

The circulation provides new aminoalkylidene-amino-1,4-dihydropyridines which influence the circulatory system and are useful, for instance, as antihypertensive agents. Also included in the invention are methods for the preparation of said dihydropyridines, compositions containing them and methods for their use.

Aminoalkylideamino-1,4-dihydropyridines and their use as medicaments

4,5-Dihydropyridines bearing an N,N-disubstituted amino group in the 2-position, carbonyl functions in the 3- and 5-positions and being optionally substituted in the 6-position by lower alkyl or phenyl and, in the 4-position by lower alkyl, phenyl, substituted phenyl or a heterocyclic group, are antihypertensive agents and coronary vessel dilators. The compounds, of which 2-pyrrolidino-6-methyl-4-(3-nitrophenyl)-4,5-dihydropyridine-3,5-dicarboxy lic acid 3,5-diethyl ester is a representative embodiment, are prepared through condensation of an ylideneacetoacetic acid ester and a substituted 3,3-diaminoacrylate.

Antihypertensive 2-amino-4,5-dihydropyridine derivatives

1,4-Dihydropyridines bearing carbonyl functions in the 3- and 5-positions, being optionally substituted by lower alkyl in the 6-position, being substituted in the 4-position by lower alkyl, phenyl, substituted phenyl or a heterocyclic group, and being fused through the 1- and 2-positions to a five, six or seven membered cycloalkyl ring, one methylene group of which can be replaced by sulfur, oxygen imino or alkylimino, are anti-hypertensive agents and coronary vessel dilators. The compounds, of which 6-methyl-4-(3-nitrophenyl)-1,2-pentamethylene-1,4-dihydropyridine-3,5-dica rboxylic acid 3,5-diethyl ester is a representative embodiment, are prepared through condensation of an ylideneacetoacetic acid ester and a cyclic enamino carbonyl derivative.

Growing community of inventors

Opladen, Germany

Wulf Vater